Evidence map›Paper›PMID 38904884›Full record

ArticleTherapeutic innovation & regulatory science2024

Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: "It's About Time we Bring Trials to People".

Dawn P Richards, John Queenan, Linnea Aasen-Johnston, Heather Douglas, Terry Hawrysh, Michael Lapenna, Donna Lillie, Emily I McIntosh, Jenna Shea, Maureen Smith and 1 more

Abstract read
In one paragraph

Article in Therapeutic innovation & regulatory science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dawn P RichardsClinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada. dawn.richards@ctontario.ca.ORCID 0000-0003-1151-0826
John QueenanDepartment of Public Health Sciences, Queen's University, K7L 3N6, Kingston, ON, Canada.
Linnea Aasen-JohnstonBESPOKE Business Solutions Inc, 135 Coons Road, L4E 2M9, Richmond Hill, ON, Canada.
Heather DouglasCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Terry HawryshCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Michael LapennaCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Donna LillieCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Emily I McIntoshCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Jenna SheaCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Maureen SmithCollege of Lived Experience Member, Clinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.
Susan MarlinClinical Trials Ontario, MaRS Centre, West Tower, 661 University Avenue, Suite 460, M5G 1M1, Toronto, ON, Canada.

Funding

Clinical Trials Ontario N/A
6 · The paper itself

Abstract

backgroundLittle is known about patient and the public perspectives on decentralized and hybrid clinical trials in Canada.

methodsWe conducted an online survey (English and French) promoted on social media to understand perspectives of people in Canada about decentralized and hybrid clinical trials. The survey had two sections. We co-produced this project entirely with patient, caregiver, and family partners.

resultsThe survey had 284 (14 French) individuals who started or completed Section 1, and 180 (16 French) individuals who started or completed Section 2. People prefer to have options to participate in clinical trials where aspects are decentralized or hybridized. 79% of respondents preferred to have options related to study visits. There were concerns about handling adverse events or potential complications in decentralized trials, however, communication options such as a dedicated contact person for participants was deemed helpful. Most respondents were amenable to informed consent being done at a satellite site closer to home or via technology and were split on privacy concerns about this. Most preferred travel to a site within an hour, depending on what the trial was for or its impact on quality of life. Due to the response rate, we were unable to explore associations with gender, age, health status, geography, ethnicity, and prior clinical trial participation.

conclusionOur findings indicate an openness in Canada to participating in trials that decentralize or hybridize some aspects. These trials are perceived to provide benefits to participants and ways to increase equity and accessibility for participants.

Indexed as

Clinical Trials as TopicPublic OpinionAdolescentAdultAgedCanadaFemaleHumansInformed ConsentMaleMiddle AgedSocial MediaSurveys and QuestionnairesYoung AdultDecentralized clinical trialsHybrid clinical trialsPatient PerceptionsPatient PerspectivesPublic perceptionsPublic perspectivesSurvey

Identifiers

PMID38904884
PMCPMC11335844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.